Bayer's 2026 Outlook Holds Firm as Tariff and Legal Timelines Converge

Bayer's 2026 guidance holds firm despite US tariff threats and legal costs. A key Supreme Court case and strong pharma growth shape its strategic outlook.

Bayer's shares gained 2.52 percent to EUR 40.26, reflecting investor confidence as the company navigates a complex mix of trade policy and legal pressures. The market's positive reaction follows clear communication from management that newly threatened US import tariffs on pharmaceuticals are already factored into its financial planning.

Sebastian Guth, Chief Operating Officer of Bayer Pharmaceuticals and President of Bayer US, confirmed the company's 2026 guidance remains intact. This stability stems from an existing trade framework between the US and the European Union, which caps tariffs on European medicines at 15 percent. This agreement provides a crucial buffer against the much higher potential rates of up to 100 percent theoretically possible under Section 232. Consequently, Bayer continues to project an EBITDA before special items of between EUR 9.6 billion and EUR 10.1 billion for 2026, alongside stable currency-adjusted sales.

The company's financial resilience is further tested by significant legal expenditures. For the current year, Bayer anticipates a negative free cash flow, with roughly EUR 5 billion earmarked for ongoing litigation settlements. A pivotal moment arrives on April 27, when the US Supreme Court hears arguments in a case that could determine whether federal law preempts future Roundup lawsuits alleging a lack of warning labels. A ruling in Bayer's favor would structurally curb the wave of litigation, marking a potential turning point after years of costly disputes.

Investor attention is also focused on the upcoming Annual General Meeting on April 24. The board will propose a dividend of EUR 0.11 per share for 2025. This comes as the company balances these substantial outflows with robust operational performance.

Growth is being driven by a strong pharmaceuticals division, which recorded five first-time drug approvals and six positive Phase III trial results last year. Management reaffirmed its goal to increase pharmaceutical margins to around 30 percent by 2030, supported by key focus areas in oncology, cardiology, and women's health. In a related development, Guth pointed to the recent US-UK pharmaceutical agreement—which trades tariff-free access for British medicines in exchange for higher drug prices in the UK—as a potential blueprint for future global pricing negotiations.

Adding a note of external validation, the rating agency Sustainalytics recently removed its warning signal concerning glyphosate risks, acknowledging clear progress by Bayer in risk containment. As the company prepares to release quarterly figures in May, its path forward is defined by a carefully managed balance between legal resolution, trade policy navigation, and pipeline-driven growth.